Literature DB >> 15168077

[Skeletal vascular lesions in childhood and adolescence].

E Bruder1, H Kozakewich.   

Abstract

Currently, vascular lesions are being classified either as tumors with inherent proliferative potential or as vascular malformations with early manifestation and growth commensurate with the growth of the child. This new classification is also applicable to skeletal vascular lesions. 30% of all skeletal vascular lesions manifest in the first two decades of life, with a preponderance of malformations. They are attributed to disturbances in the complex cascade of angiogenesis and a minority may be hereditary. Multiple cutaneous vascular malformations are associated with mutations of the TIE2- and Glomulin-Genes. Vascular malformations with involvement of multiple skeletal elements may pursue an aggressive course and manifest as massive osteolysis. Among the epithelioid vascular tumours of bone, also in young patients, benign epithelioid hemangioma can be distinguished on a morphological basis from epithelioid hemangioendothelioma as an entity with low malignant potential.

Entities:  

Mesh:

Year:  2004        PMID: 15168077     DOI: 10.1007/s00292-004-0698-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  22 in total

1.  Vasculogenesis, angiogenesis, hemangiomas, and vascular malformations.

Authors:  M Michael Cohen
Journal:  Am J Med Genet       Date:  2002-04-01

2.  Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis.

Authors:  L W GORHAM; A P STOUT
Journal:  J Bone Joint Surg Am       Date:  1955-10       Impact factor: 5.284

3.  Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings.

Authors:  L W GORHAM; A W WRIGHT; H H SHULTZ; F C MAXON
Journal:  Am J Med       Date:  1954-11       Impact factor: 4.965

Review 4.  Vascular tumors and vascular malformations (new issues).

Authors:  O Enjolras; J B Mulliken
Journal:  Adv Dermatol       Date:  1997

5.  Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.

Authors:  M Vikkula; L M Boon; K L Carraway; J T Calvert; A J Diamonti; B Goumnerov; K A Pasyk; D A Marchuk; M L Warman; L C Cantley; J B Mulliken; B R Olsen
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

Review 6.  Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

Authors:  A Saaristo; T Karpanen; K Alitalo
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

7.  Epithelioid vascular tumors of bone: a review and proposal of a classification scheme.

Authors:  J X O'Connell; G P Nielsen; A E Rosenberg
Journal:  Adv Anat Pathol       Date:  2001-03       Impact factor: 3.875

8.  Allelic and locus heterogeneity in inherited venous malformations.

Authors:  J T Calvert; T J Riney; C D Kontos; E H Cha; V G Prieto; C R Shea; J N Berg; N C Nevin; S A Simpson; K A Pasyk; M C Speer; K G Peters; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

9.  The histiocytoid hemangiomas. A unifying concept embracing several previously described entities of skin, soft tissue, large vessels, bone, and heart.

Authors:  J Rosai; J Gold; R Landy
Journal:  Hum Pathol       Date:  1979-11       Impact factor: 3.466

Review 10.  Histiocytoid hemangioma of bone: a benign lesion which may mimic angiosarcoma. Report of a case and review of literature.

Authors:  R O Cone; P Hudkins; V Nguyen; W A Merriwether
Journal:  Skeletal Radiol       Date:  1983       Impact factor: 2.199

View more
  1 in total

1.  Vascular lesions of bone in children, adolescents, and young adults. A clinicopathologic reappraisal and application of the ISSVA classification.

Authors:  Elisabeth Bruder; Antonio R Perez-Atayde; Gernot Jundt; Ahmad I Alomari; Johannes Rischewski; Steven J Fishman; John B Mulliken; Harry P W Kozakewich
Journal:  Virchows Arch       Date:  2008-12-24       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.